



**Flow and Imaging Cytometry Resource, PCIMM,
Immune Disease Institute, Harvard Medical School
Armenise Building RM D-239
200 Longwood Avenue,
Boston, MA 02115
barteneva@idi.med.harvard.edu
phone: (617) 713-8930**

Project Based Biosafety Form

Information about the sample sources and potentially infectious agents is critical for effective biosafety measures. Consequently, this sample information form must be filled out completely and signed by the Principal Investigator who is requesting samples to be analyzed or sorted in the Flow Cytometry Core Resource (FICR). This form and Sort Request Form must be submitted for review for FICR Director before processing experiments or projects are scheduled in the flow facility.

Researcher: (individual performing experiment)

Phone:

E-mail:

Lab Location (Building/Room #):

Principal Investigator :

Phone:

E-mail:

List type of sample and source (i.e., mouse spleen cells, human peripheral blood mononuclear cells, cells from an animal en-grafted with human cells, etc.); for cell lines, describe from what type of cell the cell line was derived (e.g. murine B-lymphocyte.)

Does the sample contain any known Infectious agent(s)? If Yes, list agent(s):

YES NO

Has the Infectious agent(s) been inactivated or rendered non-infectious? (circle one)

YES NO Unknown

If yes, describe the method of inactivation.

Has this protocol been reviewed by the Institutional Biosafety Committee? (circle one):

YES NO

(If yes, state BSL and approval number and date of approval)

Were tissue/blood donors screened for the following pathogens: HIV, SIV, HepB, HepC, HepD, Herpesvirus simiae, HTLV-1, HTLV-2, LCMV, SARS, Mycobacterium tuberculosis or Mycobacterium bovis or Neisseria meningitidis? (circle one):

YES NO Unknown

Results: (circle one): Positive Negative

Could the sample contain other known human pathogens? Yes No

If yes, list agent(s):

Were cells transformed using a virus such as EBV, HTLV-1, herpes, Saimirii or other virus? If yes, please list virus:

YES NO

Were the cells genetically engineered? YES NO

If yes, how were they genetically engineered? Was a viral vector (adenovirus, retrovirus, lentivirus, herpesvirus, etc.) used to transfer genetic information to the cells?

If yes, is the used virus: (circle one) *replication-competent*. or *replication-incompetent* ?
If yes describe method and show packaging cell line.

Will the samples be fixed prior to submission to core flow cytometry laboratory?

YES NO

Please describe the fixation protocol in detail, e.g. list concentration and exposure time.

I have read the above questions carefully and certify that the information provided to be accurate and correct.

Signature:
(Researcher): _____ Date: _____

Signature:
(Principal Investigator) _____ Date: _____

Review: (Circle One) Approved Disapproved

Signature: _____ Date: _____

Dr. Natasha Barteneva, MD, PhD, FICR Director